A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee

PHASE3CompletedINTERVENTIONAL
Enrollment

403

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

October 31, 2000

Study Completion Date

October 31, 2000

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

acetaminophen

Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.

DRUG

Rofecoxib

Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.

DRUG

Rofecoxib

Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.

All Listed Sponsors
lead

Johnson & Johnson Consumer and Personal Products Worldwide

INDUSTRY

NCT00568295 - A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter